Drug Development Pipeline
Restore CFTR Function
QBW251 is a type of CFTR Modulator called a “potentiator”. Similar to the drug ivacaftor, this drug would help to facilitate the opening of the chloride channel on the cell surface. This compound is administered through an oral pill.
Phase 2a trials were completed in people with CF with residual function mutations. No further development in CF is planned at this time.
This program is sponsored by Novartis and was conducted within the Therapeutics Development Network.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More